{"id":"half-boosted-fosamprenavir","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Elevated transaminases"}]},"_chembl":{"chemblId":"CHEMBL1664","moleculeType":"Small molecule","molecularWeight":"585.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosamprenavir is a prodrug of amprenavir that inhibits HIV protease, preventing the cleavage of viral polyproteins necessary for viral maturation and infectivity. The 'half-boosted' designation indicates a reduced dose of ritonavir (a CYP3A4 inhibitor) is used to enhance fosamprenavir plasma concentrations, potentially improving tolerability while maintaining antiviral efficacy.","oneSentence":"Half-boosted fosamprenavir is an HIV protease inhibitor that blocks viral protease enzyme activity with reduced ritonavir boosting compared to standard fosamprenavir formulations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:48.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve or treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT00363142","phase":"PHASE3","title":"A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"HIV Infection, Infection, Human Immunodeficiency Virus","enrollment":211}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":265,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Half-boosted Fosamprenavir","genericName":"Half-boosted Fosamprenavir","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Half-boosted fosamprenavir is an HIV protease inhibitor that blocks viral protease enzyme activity with reduced ritonavir boosting compared to standard fosamprenavir formulations. Used for HIV-1 infection in treatment-naïve or treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}